title: A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product.
abstract: Cilostazol is a selective inhibitor of type 3 phosphodiesterase. 5-(3-Chloropropyl)-1-cyclohexyl-1H-tetrazole, used as an intermediate in the synthesis of cilostazol, has a primary alkyl chloride group, a well-known alerting function for genotoxic activity. Upon request from a regulatory agency, a limit test in accordance with ICH Q2(R1) added with the accuracy of a recovery test of 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole in cilostazol was developed and validated. The application of the method highlighted the need to optimize the purification process to ensure levels of this potential genotoxic impurity in the final active pharmaceutical ingredient below the established limit. Also, the analytical method was suitable to determine the amount of the impurity in samples of the commercially available drug product, which showed the levels to be above the established threshold of toxicological concern (TTC).
authors.affiliation: R&D Department, Dipharma Francis srl, Via Bissone 5, Baranzate (MI), Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Bray
authors.affiliation: R&D Department, Dipharma Francis srl, Via Bissone 5, Baranzate (MI), Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Monzani
authors.affiliation: R&D Department, Dipharma Francis srl, Via Bissone 5, Baranzate (MI), Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Brunoldi
authors.affiliation: R&D Department, Dipharma Francis srl, Via Bissone 5, Baranzate (MI), Italy.
authors.forename: Pietro
authors.initials: P
authors.lastname: Allegrini
keywords: Cilostazol; HPLC/MS; Limit test method; Potential genotoxic impurity; Validation
references.citation: Ann Pharmacother. 2001 Jan;35(1):48-56
references.pmid: 11197586
references.citation: Regul Toxicol Pharmacol. 2006 Apr;44(3):198-211
references.pmid: 16412543
references.citation: J Pharm Biomed Anal. 2011 Jun 25;55(4):662-7
references.pmid: 21193280
references.citation: J Pharm Biomed Anal. 2008 Nov 4;48(3):497-507
references.pmid: 18657926
references.citation: Toxicol Lett. 2004 Jun 15;151(1):29-41
references.pmid: 15177638
references.citation: J Pharm Sci. 2013 May;102(5):1404-18
references.pmid: 23436613
references.citation: Environ Mutagen. 1985;7(6):919-21
references.pmid: 4065064
references.citation: Proc Natl Acad Sci U S A. 1973 Mar;70(3):782-6
references.pmid: 4577135